Advertisement

Picture Eurasanté BioFIT 2017 Strasbourg France November 600x60px
Document › Details

Concept Life Sciences Holdings Ltd.. (10/30/17). "Press Release: Concept Life Sciences Announces Acquisition of Aquila BioMedical". Manchester.

Organisations Organisation Concept Life Sciences, Manchester
  Group Concept Life Sciences (Group)
  Organisation 2 Aquila BioMedical Ltd.
  Group Concept Life Sciences (Group)
Products Product preclinical research
  Product 2 cancer immunotherapy (immuno-oncology, I-O)
Index term Index term Aquila BioMedical~Concept Life Sciences: investment, 201710 acquisition of Aquila BioMedical Ltd by Concept Life Sciences
Persons Person Fort, Michael (Concept Life Sciences 201708 Executive Chairman)
  Person 2 Marriage, Howard (Aquila BioMedical 201308 Chairman)
     


Acquisition adds immuno-oncology capability to broaden Concept’s range of integrated drug discovery and development services


Concept Life Sciences (Concept), the integrated drug discovery, development and analytical services company, today announced it has acquired Aquila BioMedical (Aquila), the innovative pre-clinical contract research organisation with expertise in immuno-oncology, immunology and multiplex histology. Aquila is based in Edinburgh, Scotland.

Aquila’s world-leading expertise focuses on the development of therapeutics for oncology, biomarker discovery, and target expression, with services covering a wide range of in vitro and in vivo proof-of-concept studies. The acquisition is a pivotal addition to the comprehensive range of integrated services Concept provides, supporting customers throughout the drug discovery and development process. Aquila was formed in 2011 by experts from The University of Edinburgh.

Aquila has developed novel technologies to help customers to better understand the cellular and molecular events that occur with compound administration. Bespoke assays allow both phenotypic screening and target based research methods, to enable hit identification and optimisation of compound and target selection, directly increasing the compound success rate and reducing the overall cost associated with drug development.

Michael Fort, Executive Chairman, Concept Life Sciences, said: “We are excited to add Aquila to the Concept group. The company’s offering in translational biology adds significant value to our current discovery services, and broadens the wider group’s therapy offering. Both Aquila and Concept have been built around the same value of working closely with customers to tailor services according to the project objectives, and together we will provide high quality, integrated solutions.”

Professor Stephen Anderton, co-founder of Aquila Biomedical and Professor of Therapeutic Immunology at Edinburgh University, commented: “We are delighted to be joining the Concept Life Sciences group at this stage in both companies' development cycles. Concept's size, business development network and complementary scientific capacity will make the enhanced service offering attractive to the widest group of international clients, and will significantly accelerate our growth.”

Dr Howard Marriage, Entrepreneur and co-founder and Chairman of Aquila BioMedical said: “The board is immensely grateful to Clare Doris, COO, and her talented and committed team of 25 staff who have built an international client base and profitable business over the last six years. I look forward to the continued development of the Aquila contribution to Concept Life Science from their base in Edinburgh’s BioQuarter.”

Professor Jonathan Seckl, Vice Principal of Planning, Resources and Research Policy at the University of Edinburgh, said: “We congratulate the Aquila team on this milestone in their approach to building advanced biology into innovative drug discovery. This investment highlights the University’s commitment to successfully translating our world-class research into practical application by industry.”


ENDS

Photo: Aquila site at Edinburgh BioQuarter. For a high-resolution image please contact Zyme Communications


Media contact

Katie Odgaard
Zyme Communications
E: katie.odgaard@zymecommunications.com
T: +44 (0)7787 502 947


About Concept Life Sciences www.conceptlifesciences.com

Concept Life Sciences provides integrated, high quality drug discovery, development and analytical services to the life science sector. Formed as a result of targeted acquisition and organic growth, the Company has the in-house expertise and resource to support customers with projects spanning from target discovery to the clinic, adding value and IP throughout the discovery pathway.

With a track record of delivering knowledge-based, science-led solutions, the Company employs over 700 FTEs, including more than 500 highly skilled, experienced scientists, supporting its global client base from 11 state of the art laboratory facilities.

Concept Life Sciences has worked with all of the top 10 pharma and biotech companies, and is targeting revenues exceeding $60m in 2017. Having experienced rapid growth, the Company remains focused on problem solving, quality, collaboration, and flexibility.


About Aquila BioMedical, Ltd.

Aquila BioMedical, Ltd. is an innovative preclinical contract research organization that offers clients world leading research expertise in Immuno-Oncology, Immunology and Multiplex Histology. Tailored services combine advanced models with protocolled techniques, to provide high-value data, defining both efficacy and the mechanism of action of drug candidate compounds. Aquila partners with world-leading academics to provide expert advice and data interpretation.

   
Record changed: 2017-10-30

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px

More documents for Concept Life Sciences (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Eurasanté BioFIT 2017 Strasbourg France November 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px